Abstract

This is a multifaceted program including (1) synthesis and preclinical evaluation of new antineoplastic agents, (2) mechanisms and modulation of resistance to cytotoxic drugs and radiation, (3) phase I clinical trials of new agents and treatment approaches and (4) clinical pharmacokinetics and pharmacodynamics of anticancer drugs. The Developmental Therapeutics Program brings together faculty in five Departments, two Committees, the Ben May Institute and the College, fostering collaborative research efforts. The Program has the capacity to develop drugs from initial synthesis through phase I clinical testing. The Developmental Therapeutics Program is also the primary user of the new Pharmacology Core Facility which will also be used in collaborative projects with both the Clinical Investigations and Immunology and Cancer Programs. The Program also serves as a resource for training in cancer pharmacology and antineoplastic drug development, and it is partially supported by training grants from the NIH.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-25
Application #
6268770
Study Section
Project Start
1998-08-01
Project End
1999-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
25
Fiscal Year
1998
Total Cost
Indirect Cost

  Institution

Name
University of Chicago
Department
Type
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637

  Publications

Hope, C Matthew; Webber, Jemma L; Tokamov, Sherzod A et al. (2018) Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression. Elife 7:
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Wu, Chengyue; Pineda, Federico; Hormuth 2nd, David A et al. (2018) Quantitative analysis of vascular properties derived from ultrafast DCE-MRI to discriminate malignant and benign breast tumors. Magn Reson Med :
Meisel, Marlies; Hinterleitner, Reinhard; Pacis, Alain et al. (2018) Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557:580-584
Ni, Kaiyuan; Lan, Guangxu; Chan, Christina et al. (2018) Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nat Commun 9:2351
Wei, Jiangbo; Liu, Fange; Lu, Zhike et al. (2018) Differential m6A, m6Am, and m1A Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm. Mol Cell 71:973-985.e5
Webber, Jemma L; Zhang, Jie; Massey, Alex et al. (2018) Collaborative repressive action of the antagonistic ETS transcription factors Pointed and Yan fine-tunes gene expression to confer robustness in Drosophila. Development 145:
Szmulewitz, Russell Z; Peer, Cody J; Ibraheem, Abiola et al. (2018) Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol 36:1389-1395
Boisclair Lachance, Jean-François; Webber, Jemma L; Hong, Lu et al. (2018) Cooperative recruitment of Yan via a high-affinity ETS supersite organizes repression to confer specificity and robustness to cardiac cell fate specification. Genes Dev 32:389-401
Kudron, Michelle M; Victorsen, Alec; Gevirtzman, Louis et al. (2018) The ModERN Resource: Genome-Wide Binding Profiles for Hundreds of Drosophila and Caenorhabditis elegans Transcription Factors. Genetics 208:937-949

Showing the most recent 10 out of 668 publications